RecAP: Phase II started

AM-Pharma began the double-blind, placebo-controlled, international Phase II STOP-AKI trial to evaluate 0.4, 0.8 and 1.6 mg/kg IV RecAP once daily for 3 days in about 290 patients with sepsis-associat...